Effect of stunning of diagnostic 131-iodine doses on ablative doses for differentiated thyroid cancer patient’s outcome
| Autor: | Abdullah Al-Zahrani, Hiji Al-Sakhri, K. Khaled Elsaban |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Cancer Research
business.industry medicine.medical_treatment Stunning Thyroid Group ii chemistry.chemical_element Ablation Iodine medicine.disease medicine.anatomical_structure Oncology chemistry Absorbed dose Ablative case medicine Radiology Nuclear Medicine and imaging Nuclear medicine business Thyroid cancer |
| Zdroj: | Journal of Solid Tumors. 3 |
| ISSN: | 1925-4075 1925-4067 |
| DOI: | 10.5430/jst.v3n6p11 |
| Popis: | Background: Thyroid stunning was defined as transient reduction of thyroid tissue uptake 131I (RAI-131) ablative dose after a diagnostic 131I dose that decreases the final absorbed dose in ablative therapy. Aim of the study: after following the proper precautions compare the response to the ablative dose given to patients with differentiated thyroid cancer with or without diagnostic radioactive iodine 131(RAI-131). Patients and methods: One hundred patients with differentiated thyroid cancer were included and divided into two groups: Group I, ablative dose of RAI-131according to their risk stratification without diagnostic dose and Group II, patients performing diagnostic whole body scan [5mCi] followed by ablative dose. Results: The current study have showed no significant associations between overall response in both groups and the different studied parameters except for the mean ablative dose of RAI-131 [r=0.9; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|